| Literature DB >> 30477490 |
Chenxia Han1, Feng Li2, Simin Tian3, Yan Liu1, Huai Xiao4, Xiumei Wu4, Weiyue Zhang1, Wei Zhang1, Meng Mao1.
Abstract
BACKGROUNDS: Although the physical and mental enhancement effect of essential oils have been proved, the beneficial effect of essential oil in central fatigue remains unclear. In this study, we extracted essential oils from nine aromatic plants to make a compound essential oil, and detected the therapeutic effect of central fatigue by daily aerial diffusion.Entities:
Keywords: Central fatigue; Essential oil; Traditional Chinese medicine
Mesh:
Substances:
Year: 2018 PMID: 30477490 PMCID: PMC6260882 DOI: 10.1186/s12906-018-2375-6
Source DB: PubMed Journal: BMC Complement Altern Med ISSN: 1472-6882 Impact factor: 3.659
Fig. 1Peak marked with retention time. The result of GC-MS analysis of the compound essential oil, the main components were showed as the marked peak with retention time
Identified components of the compound essential oil
| No. | Retention time (min) | Relative Content (%) | Compound | Molecular weight | Similarity (%) |
|---|---|---|---|---|---|
| 1 | 4.787 | 0.55 | hexamethyl cyclotrisiloxane | 222.056 | 95 |
| 2 | 7.442 | 0.86 | (1S)-2,6,6-trimethylbicyclo[3.1.1]hept-2-ene | 136.125 | 97 |
| 3 | 8.62 | 2.31 | (1S)-6,6-dimethyl-2-methylene-bicyclo[3.1.1]heptane | 136.125 | 97 |
| 4 | 9.053 | 0.30 | (−) | ||
| 5 | 9.108 | 0.38 | (−) | ||
| 6 | 9.442 | 0.27 | (−) | ||
| 7 | 10.142 | 15.46 | Tricyclo[5.3.0.0(3,9)]decane | 136.125 | 90 |
| 8 | 10.264 | 0.78 | eucalyptol | 154.136 | 98 |
| 9 | 13.752 | 0.40 | trans-5-methyl-2-(1-methylethyl)- cyclohexanone | 154.136 | 98 |
| 10 | 13.852 | 5.72 | cis-5-methyl-2-(1-methylethyl)-cyclohexanone | 154.136 | 93 |
| 11 | 14.152 | 3.04 | l-menthone | 154.136 | 96 |
| 12 | 14.297 | 0.39 | (1α,2β,5α)-5-methyl-2-(1-methylethyl)-cyclohexanol | 156.151 | 91 |
| 13 | 14.441 | 10.31 | 2,6-dimethyl-2,6-octadiene | 138.141 | 90 |
| 14 | 14.919 | 0.27 | alpha-terpineol | 154.136 | 93 |
| 15 | 16.285 | 0.47 | pulegone | 152.12 | 98 |
| 16 | 16.685 | 0.27 | 3-methyl-6-(1-methylethyl)-2-cyclohexen-1-one | 152.12 | 95 |
| 17 | 17.785 | 1.67 | menthyl acetate | 198.162 | 91 |
| 18 | 18.729 | 0.48 | dodecamethyl-cyclohexasiloxane | 444.113 | 90 |
| 19 | 21.096 | 1.22 | caryophyllene | 204.188 | 99 |
| 20 | 21.962 | 3.25 | (−) | ||
| 21 | 22.107 | 0.32 | (1S-exo)-2-methyl-3-methylene-2-(4-methyl-3-pentenyl)- bicyclo[2.2.1]heptane | 204.188 | 90 |
| 22 | 22.207 | 0.38 | ethyl- 3-phenyl-2-propenoic acid ester | 176.084 | 98 |
| 23 | 22.651 | 0.25 | 1-(1,5-dimethyl-4-hexenyl)-4-methyl-benzene | 202.172 | 98 |
| 24 | 22.962 | 0.25 | di-epi-α-cedrene | 204.188 | 96 |
| 25 | 23.084 | 0.66 | tetradecamethyl-cycloheptasiloxane | 518.132 | 91 |
| 26 | 23.651 | 0.51 | (1S-cis)-1,2,3,5,6,8a-hexahydro-4,7-dimethyl-1-(1-methylethyl)-naphthalene, | 204.188 | 97 |
| 27 | 23.729 | 3.63 | (−) | ||
| 28 | 24.273 | 0.85 | [1R-(1α,3α,4β)]-4-ethenyl-4-trimethyl-3-(1-methylethenyl)-cyclohexanemethanol | 222.198 | 91 |
| 29 | 24.573 | 2.32 | nerolidol | 222.198 | 91 |
| 30 | 25.373 | 10.19 | (−) | ||
| 31 | 25.928 | 0.98 | 8-epi-γ-eudesmol | 222.198 | 95 |
| 32 | 26.195 | 0.84 | gama.-eudesmol | 222.198 | 99 |
| 33 | 26.673 | 3.66 | (−) | ||
| 34 | 26.795 | 0.91 | 7-epi-α-selinene | 204.188 | 95 |
| 35 | 27.017 | 0.37 | (−) | ||
| 36 | 27.184 | 5.14 | (−) | ||
| 37 | 27.517 | 0.69 | Z-α-trans-bergamotol, | 220.183 | 91 |
| 38 | 27.784 | 0.33 | E-cis,epi-α-santalol, | 220.183 | 97 |
| 39 | 28.084 | 2.38 | (−) | ||
| 40 | 28.173 | 0.52 | methyl tetradecanoate | 242.225 | 99 |
| 41 | 29.017 | 0.89 | Cis-lanceol | 220.183 | 90 |
| 42 | 30.306 | 3.66 | isopropyl myristate | 270.256 | 95 |
| 43 | 32.294 | 0.33 | methyl hexadecanoic acid ester | 270.256 | 99 |
| 44 | 34.916 | 0.26 | 13-hexyloxacyclotridec-10-en-2-one | 280.24 | 93 |
| 45 | 35.472 | 0.64 | (E,E)- methyl-9,12-octadecadienoic acid ester | 294.256 | 99 |
| 46 | 35.583 | 0.66 | Methyl-11-octadecenoic acid ester | 296.272 | 99 |
| 47 | 36.061 | 0.27 | methyl stearate | 298.287 | 99 |
| 48 | 38.938 | 9.70 | [R-(Z)]-12-hydroxy-, methyl-9-octadecenoic acid ester | 312.266 | 94 |
(−) not identified
Fig. 2Bodyweight. All data were represented as the mean ± SEM (n = 11), ***refers to p < 0.001 vs CSD group. The bodyweight of CON rats increased significantly compared with the CSD rats (a). Details of daily body weight changes, as recorded at 9:00 during training days (b). The growth of bodyweight of CON group exhibited a higher growing trend
Fig. 3Swimming time of weight loaded forced swimming test. All data were represented as the mean ± SEM (n = 11), *** refers to p < 0.001 vs CSD group. The swimming time of CON group was significantly longer compared with CSD group, CEO increased the swimming time significantly compared with the CSD group
Fig. 4Assessment of open field test. All indexes were recorded in a test of 5 min. All data were represented as the mean ± SEM (n = 11), * refers to p < 0.05, *** refers to p < 0.000 vs. CSD group. The time spent in center of CON group was significantly shorter compared with CSD group, and CEO decreased the central time (a). The total distance travelled (b), number of crossing squares (c), max continuous distance (d), mean velocity (e) of CON group all decreased significantly compared with CSD group respectively, and treatment of CEO showed a reduction trend on these parameters. Number and time recorded of vertical activity (f, g) showed the same situation as horizontal activity. No significant difference was found in the number of grooming behavior (h). The time of grooming (i) in CON group were significantly higher than CSD group. Number of defecations (j) of CSD group increased significantly compared with CON group, and CEO was seen to decrease the measure significantly
Fig. 5Assessment of elevated plus maze. All data were represented as the mean ± SEM (n = 11), * refers to p < 0.05 **refers to p < 0.01 vs. CSD group. The ratio of number of entries in the open /total entries (a) in CSD group decreased significantly compared with CON group. CEO increased the ratio. There was no significant difference in the ratio of time spent in open/total arms (b), whereas the trend showed same as before. The reduction of central time (c) in CSD was not significant, however the treatment CEO increased the measure compared with CSD group